ALXN-GEVA premium is the third-largest ever (largest for a biotech) for a US deal valued at $5B or more: http://blogs.wsj.com/moneybeat/2015/05/06/alexion-pharmaceuticals-premium-for-synageva-is-fourth-highest-on-record/